Zhang Kaixuan, Shi Yajun, Peng Lirong, Zhang Xiaofei, Zheng Nanbo, Xin Jiajing, Zou Junbo, Luan Fei
Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, School of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, 712046, People's Republic of China.
Department of Pharmacy, Xi'an Central Hospital, Xi'an, Shaanxi, 710000, People's Republic of China.
J Multidiscip Healthc. 2025 Aug 21;18:5125-5145. doi: 10.2147/JMDH.S533730. eCollection 2025.
This study leverages quantitative analysis to delve into the current state, key focal points, and developmental trajectory of research on gut microbiota and its metabolites in relation to cardiovascular diseases, offering guidance for future exploration.
Utilizing software tools such as VOSviewer, CiteSpace, and Scimago Graphica, we conducted a multidimensional analysis. This analysis aimed to accurately evaluate the current research landscape and emerging focal points in the field of gut microbiota and cardiovascular disease research, both domestically and internationally. Moreover, it also uncovers the future trends of gut microbiota in cardiovascular disease research.
We included 4,348 articles and reviews examining the relationship between gut microbiota and cardiovascular diseases. Researchers from 105 countries and regions, 4,411 institutions, and 20,600 authors have contributed to this field. Key research topics include the Mediterranean diet, gut microbiota metabolites, coronary heart disease, myocardial infarction, atherosclerosis, probiotics, and prebiotics. Recently, there has been a significant increase in the frequency of specific keywords such as bile acid, trimethylamine oxide, and coronary artery disease.
This study underscores the promising research prospects of gut microbiota and its metabolites in cardiovascular disease research. Their potential application value is expected to promote the sustainable development and innovation of related fields.